NeoGenomics Inc
NEO
18.34USD+0.40Â (+2.23%)Market ClosedWatchlist
Market Summary
USD18.34+0.40
Market Closed2.23%
NEO Stock Price
View Fullscreen
NEO RSI Chart
NEO Valuation
NEO Price/Sales (Trailing)
NEO Profitability
NEO Fundamentals
NEO Revenue
NEO Earnings
Price Action
Last 7 days
-3.5%
Last 30 days
15.9%
Last 90 days
34.9%
Trailing 12 Months
52.0%
How does NEO drawdown profile look like?
NEO Financial Health
NEO Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
| Year | Q1 | Q2 | Q3 | Q4 |
|---|---|---|---|---|
| 2023 | 529.8M | 551.6M | 574.8M | 0 |
| 2022 | 486.0M | 489.3M | 496.8M | 509.7M |
| 2021 | 454.0M | 488.7M | 484.6M | 484.3M |
| 2020 | 419.3M | 404.5M | 425.3M | 444.4M |
| 2019 | 308.9M | 342.9M | 378.4M | 408.8M |
| 2018 | 246.2M | 251.7M | 261.7M | 276.7M |
| 2017 | 241.8M | 240.9M | 239.3M | 240.3M |
| 2016 | 136.5M | 175.2M | 210.9M | 244.1M |
| 2015 | 91.9M | 95.6M | 97.5M | 99.8M |
| 2014 | 69.0M | 74.1M | 80.4M | 87.1M |
| 2013 | 60.4M | 60.4M | 63.0M | 66.5M |
| 2012 | 49.8M | 55.0M | 57.9M | 59.9M |
| 2011 | 36.6M | 38.9M | 41.2M | 43.5M |
| 2010 | 0 | 0 | 0 | 34.4M |
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for NEO
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
| Dec 01, 2023 | stone warren | sold (taxes) | - | - | -5,431 | president, clinical services |
| Nov 17, 2023 | olivo alicia c | sold | -49,082 | 18.39 | -2,669 | general counsel |
| Sep 30, 2023 | olivo alicia c | sold (taxes) | - | - | -14.00 | general counsel |
| Sep 01, 2023 | olivo alicia c | sold (taxes) | - | - | -1,666 | general counsel |
| Aug 01, 2023 | olivo alicia c | sold (taxes) | - | - | -14.00 | general counsel |
| Jun 01, 2023 | sikri vishal | sold (taxes) | - | - | -21,406 | president advanced diagnostics |
| May 22, 2023 | tetrault lynn a. | acquired | 17,481 | 11.6 | 1,507 | - |
| May 01, 2023 | olivo alicia c | sold (taxes) | - | - | -662 | general counsel |
| Apr 01, 2023 | kulkarni shashikant | sold (taxes) | - | - | -3,759 | chief scientific officer |
| Mar 02, 2023 | dieter cynthia j | sold (taxes) | - | - | -117 | chief accounting officer |
Which funds bought or sold NEO recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
| Dec 06, 2023 | CITIGROUP INC | reduced | -44.39 | -915,093 | 678,087 | -% |
| Dec 06, 2023 | Raleigh Capital Management Inc. | unchanged | - | -720 | 2,349 | -% |
| Dec 04, 2023 | TUCKER ASSET MANAGEMENT LLC | unchanged | - | -754 | 2,460 | -% |
| Nov 24, 2023 | DEUTSCHE BANK AG\ | added | 6.95 | -275,374 | 1,242,950 | -% |
| Nov 22, 2023 | KBC Group NV | unchanged | - | - | 162,000 | -% |
| Nov 22, 2023 | Public Sector Pension Investment Board | reduced | -30.37 | -1,699,570 | 1,939,510 | 0.01% |
| Nov 22, 2023 | Graham Capital Management, L.P. | reduced | -33.02 | -453,115 | 476,711 | 0.01% |
| Nov 21, 2023 | Walleye Capital LLC | new | - | 331,018 | 331,018 | -% |
| Nov 21, 2023 | COMERICA BANK | new | - | 790,053 | 790,053 | -% |
| Nov 21, 2023 | COMERICA BANK | sold off | -100 | - | - | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
Schedule 13G FIlings of NeoGenomics Inc
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| Feb 10, 2023 | artisan partners limited partnership | 0.0% | 10 | SC 13G/A | |
| Feb 09, 2023 | vanguard group inc | 10.83% | 13,674,745 | SC 13G/A | |
| Feb 09, 2023 | brown advisory inc | 5% | 6,337,008 | SC 13G | |
| Feb 06, 2023 | wellington management group llp | 0.00% | 0 | SC 13G/A | |
| Jan 23, 2023 | blackrock inc. | 17.4% | 21,932,623 | SC 13G/A | |
| Feb 04, 2022 | wellington management group llp | 8.99% | 11,069,283 | SC 13G | |
| Feb 04, 2022 | artisan partners limited partnership | 6.3% | 7,732,355 | SC 13G | |
| Jan 27, 2022 | blackrock inc. | 15.7% | 19,328,254 | SC 13G/A | |
| Jan 26, 2022 | blackrock inc. | 15.7% | 19,328,254 | SC 13G | |
| Feb 10, 2021 | vanguard group inc | 10.06% | 11,167,578 | SC 13G/A |
Recent SEC filings of NeoGenomics Inc
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Dec 05, 2023 | 4 | Insider Trading | |
| Nov 20, 2023 | 4 | Insider Trading | |
| Nov 17, 2023 | 144 | Notice of Insider Sale Intent | |
| Nov 06, 2023 | 8-K | Current Report | |
| Nov 06, 2023 | 10-Q | Quarterly Report | |
| Oct 03, 2023 | 4 | Insider Trading | |
| Sep 05, 2023 | 4 | Insider Trading |
NEO Fair Value
Loading...
Peers (Alternatives to NeoGenomics Inc)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
DHR | 160.7B | 29.6B | 10.51% | -19.98% | 27.16 | 5.44 | -5.39% | -12.54% |
IDXX | 44.1B | 3.6B | 24.23% | 23.99% | 53.65 | 12.3 | 7.43% | 22.86% |
A | 37.3B | 7.0B | 16.28% | -18.61% | 32.89 | 5.33 | 5.03% | -14.68% |
DGX | 15.2B | 9.3B | 1.84% | -9.68% | 19.95 | 1.64 | -9.69% | -38.22% |
EXAS | 11.7B | 2.4B | 2.99% | 40.82% | -41.48 | 4.86 | 19.99% | 60.62% |
| MID-CAP | ||||||||
CRL | 10.5B | 4.2B | 16.20% | -2.67% | 22.08 | 2.49 | 11.49% | 8.84% |
MEDP | 8.7B | 1.8B | 2.84% | 34.94% | 31.81 | 4.88 | 29.62% | 20.49% |
NTRA | 6.9B | 988.7M | 40.66% | 50.03% | -13.86 | 7 | 27.41% | 8.51% |
NEOG | 3.9B | 919.1M | 17.21% | 17.06% | -147.97 | 4.28 | 73.02% | -172.93% |
GH | 3.0B | 535.8M | 8.75% | -45.64% | -7.02 | 5.66 | 24.38% | 26.34% |
| SMALL-CAP | ||||||||
CDNA | 531.2M | 297.1M | 54.98% | -22.82% | -5.87 | 1.79 | -6.74% | -21.60% |
ACRS | 71.5M | 21.4M | -81.47% | -93.49% | -0.62 | 3.34 | -8.80% | -39.66% |
AWH | 31.2M | 9.2M | -11.33% | -33.68% | -1.76 | 3.4 | 16.43% | 48.38% |
APDN | 12.0M | 13.4M | -4.35% | -39.31% | -1.21 | 0.9 | -26.43% | -20.54% |
BIOC | 120.4K | - | -82.76% | -93.43% | 0 | 0.76 | -57.78% | -93.13% |
NeoGenomics Inc News
Latest updates
Financials for NeoGenomics Inc
Income Statement (Last 12 Months)
| Income Statement (Quarterly) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Revenue | 3.4% | 151,954,000 | 146,917,000 | 137,220,000 | 138,705,000 | 128,782,000 | 125,072,000 | 117,169,000 | 125,732,000 | 121,340,000 | 121,724,000 | 115,533,000 | 125,997,000 | 125,444,000 | 86,977,000 | 106,030,000 | 106,868,000 | 104,672,000 | 101,713,000 | 95,577,000 | 76,475,000 | 69,097,000 |
| Gross Profit | 4.0% | 62,311,000 | 59,891,000 | 54,814,000 | 56,825,000 | 48,893,000 | 43,946,000 | 38,232,000 | 45,257,000 | 47,239,000 | 52,990,000 | 41,574,000 | 57,453,000 | 54,065,000 | 28,006,000 | 46,369,000 | 49,923,000 | 50,832,000 | 48,966,000 | 47,115,000 | 37,111,000 | 32,321,000 |
| Operating Expenses | -3.7% | 86,506,000 | 89,785,000 | 89,887,000 | 83,208,000 | 88,403,000 | 83,648,000 | 90,260,000 | 86,824,000 | 86,952,000 | 75,357,000 | 56,681,000 | 51,914,000 | 49,396,000 | 46,913,000 | 51,662,000 | 47,602,000 | 47,173,000 | 44,488,000 | 44,567,000 | 34,289,500 | 28,401,000 |
| S&GA Expenses | -6.8% | 17,610,000 | 18,901,000 | 16,259,000 | 17,142,000 | 16,809,000 | 17,071,000 | 16,299,000 | 15,917,000 | 15,704,000 | 17,224,000 | 13,749,000 | 13,105,000 | 11,304,000 | 10,195,000 | 13,258,000 | 12,302,000 | 11,508,000 | 12,324,000 | 11,216,000 | 8,047,000 | 6,900,000 |
| R&D Expenses | -29.6% | 5,285,000 | 7,502,000 | 7,395,000 | 6,675,000 | 7,312,000 | 8,626,000 | 7,713,000 | 8,513,000 | 7,409,000 | 3,495,000 | 2,456,000 | 2,100,000 | 1,964,000 | 2,105,000 | 2,060,000 | 2,080,000 | 2,611,000 | 2,587,000 | 1,209,000 | 526,000 | 446,000 |
| EBITDA Margin | 20.8% | -0.13 | -0.16 | -0.19 | -0.24 | -0.28 | -0.25 | -0.02 | 0.04 | 0.15 | 0.20 | 0.01 | 0.04 | 0.01 | 0.01 | 0.06 | - | - | - | - | - | - |
| Interest Expenses | -12.5% | -2,840,000 | -2,524,000 | 1,467,000 | 441,000 | 139,000 | 926,000 | -1,301,000 | 1,707,000 | 1,296,000 | 902,000 | 1,177,000 | 2,194,000 | 2,458,000 | 1,548,000 | 819,000 | 380,000 | 203,000 | 1,304,000 | 1,826,000 | 1,464,000 | 1,873,000 |
| Income Taxes | -27.1% | -2,935,000 | -2,309,000 | -2,925,000 | -2,837,000 | -2,772,000 | -5,730,000 | -3,753,000 | -2,445,000 | -2,822,000 | -2,437,000 | 976,000 | -7,850,000 | -335,000 | -11,132,000 | 1,089,000 | -3,861,000 | 1,348,000 | 175,000 | -2,023,000 | 1,049,000 | 54,000 |
| Earnings Before Taxes | 19.5% | -21,451,000 | -26,640,000 | -33,720,000 | -25,524,000 | -39,624,000 | -41,033,000 | -53,161,000 | -44,203,500 | -23,170,000 | 73,436,000 | -21,138,000 | 7,567,000 | 2,222,000 | -17,956,000 | -5,889,000 | 2,435,000 | 3,491,000 | 2,166,000 | -4,447,000 | 1,402,000 | 2,077,000 |
| EBT Margin | 17.9% | -0.19 | -0.23 | -0.26 | -0.31 | -0.36 | -0.33 | -0.10 | -0.03 | 0.08 | 0.13 | -0.06 | -0.03 | -0.05 | -0.04 | 0.01 | - | - | - | - | - | - |
| Net Income | 23.9% | -18,516,000 | -24,331,000 | -30,795,000 | -22,687,000 | -36,852,000 | -35,303,000 | -49,408,000 | -41,758,500 | -20,348,000 | 75,873,000 | -22,114,000 | 15,417,000 | 2,557,000 | -6,824,000 | -6,978,000 | 6,296,000 | 2,143,000 | 1,991,000 | -2,424,000 | 353,000 | 2,023,000 |
| Net Income Margin | 19.4% | -0.17 | -0.21 | -0.24 | -0.28 | -0.33 | -0.30 | -0.07 | -0.02 | 0.10 | 0.15 | -0.02 | 0.01 | -0.01 | -0.01 | 0.01 | - | - | - | - | - | - |
| Free Cashflow | -8.1% | -9,771,000 | -9,042,000 | -22,619,000 | -8,219,000 | -24,116,000 | -27,290,000 | -37,259,000 | -31,763,000 | -22,744,000 | -22,737,000 | -13,621,000 | -5,520,000 | -7,331,000 | -3,144,000 | -11,641,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Assets | -1.0% | 1,678 | 1,695 | 1,709 | 1,740 | 1,756 | 1,792 | 1,830 | 1,870 | 1,906 | 1,896 | 1,494 | 988 | 959 | 945 | 732 | 710 | 711 | 697 | 533 | 505 | 455 |
| Current Assets | 0.4% | 587 | 585 | 585 | 605 | 603 | 622 | 651 | 682 | 710 | 722 | 943 | 449 | 422 | 419 | 215 | 291 | 292 | 276 | 116 | 104 | 194 |
| Cash Equivalents | 5.9% | 306 | 289 | 276 | 263 | 266 | 284 | 306 | 317 | 341 | 369 | 612 | 229 | 233 | 295 | 86.00 | 173 | 179 | 167 | 13.00 | 10.00 | 118 |
| Inventory | -3.6% | 24.00 | 25.00 | 24.00 | 24.00 | 24.00 | 22.00 | 24.00 | 23.00 | 22.00 | 21.00 | 21.00 | 30.00 | 21.00 | 22.00 | 20.00 | 14.00 | 13.00 | 9.00 | 10.00 | 9.00 | 7.00 |
| Net PPE | -5.6% | 95.00 | 100 | 103 | 102 | 107 | 111 | 109 | 109 | 107 | 112 | 94.00 | 86.00 | 85.00 | 84.00 | 83.00 | 64.00 | 62.00 | 59.00 | 61.00 | 61.00 | 41.00 |
| Goodwill | 0% | 523 | 523 | 523 | 523 | 523 | 527 | 527 | 527 | 526 | 267 | 45.00 | 211 | 211 | 211 | 211 | 199 | 199 | 196 | 196 | 198 | 147 |
| Liabilities | -1.1% | 731 | 739 | 735 | 742 | 743 | 749 | 755 | 762 | 769 | 748 | 651 | 294 | 293 | 291 | 227 | 202 | 214 | 207 | 209 | 185 | 152 |
| Current Liabilities | -2.0% | 93.00 | 95.00 | 87.00 | 90.00 | 85.00 | 83.00 | 82.00 | 87.00 | 93.00 | 99.00 | 68.00 | 73.00 | 65.00 | 62.00 | 68.00 | 64.00 | 69.00 | 59.00 | 73.00 | 61.00 | 47.00 |
| Shareholder's Equity | -0.9% | 947 | 956 | 974 | 998 | 1,013 | 1,044 | 1,075 | 1,108 | 1,137 | 1,148 | 844 | 694 | 666 | 654 | 505 | 507 | 497 | 490 | 324 | 320 | 304 |
| Retained Earnings | -8.6% | -232 | -214 | -189 | -159 | -136 | -99.55 | -64.24 | -14.84 | 27.00 | 47.00 | -28.60 | -7.18 | -22.60 | -25.16 | -18.33 | -11.36 | -17.65 | -51.69 | -53.68 | -19.36 | -51.56 |
| Additional Paid-In Capital | 0.8% | 1,182 | 1,173 | 1,167 | 1,161 | 1,154 | 1,147 | 1,142 | 1,124 | 1,111 | 1,101 | 872 | 701 | 689 | 679 | 526 | 520 | 517 | 543 | 379 | 340 | 354 |
| Accumulated Depreciation | 5.0% | 155 | 147 | 139 | 132 | 125 | 123 | 116 | 110 | 112 | 105 | 99.00 | 93.00 | 86.00 | 80.00 | 74.00 | 69.00 | 64.00 | 59.00 | 55.00 | 50.00 | 49.00 |
| Shares Outstanding | 0.1% | 127 | 127 | 127 | 127 | 127 | 124 | 124 | 124 | 123 | 118 | 116 | 112 | 110 | 108 | 104 | 105 | 104 | 98.00 | 95.00 | 94.00 | 87.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Quarterly) | (In Thousands) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 |
| Cashflow From Operations | -255.1% | -5,497 | -1,548 | -12,692 | -3,685 | -16,272 | -16,996 | -29,040 | -19,776 | -7,767 | -1,390 | 2,210 | 5,985 | 526 | 1,882 | -6,933 | 3,359 | 18,634 | -4,721 | 6,097 | 15,453 | 8,381 |
| Share Based Compensation | 25.9% | 7,180 | 5,705 | 4,758 | 4,663 | 4,280 | 3,626 | 12,103 | 10,062 | 5,237 | 4,506 | 2,653 | 2,676 | 2,715 | 2,635 | 2,186 | 2,273 | 3,275 | 2,313 | 2,139 | 1,807 | 1,191 |
| Cashflow From Investing | 39.3% | 20,821 | 14,949 | 23,742 | -1,063 | -4,198 | -6,274 | 12,052 | -9,583 | -14,686 | -453,410 | -154,688 | -28,854 | -70,716 | -18,163 | -41,708 | -6,076 | -7,316 | -3,042 | -3,196 | -128,596 | -2,148 |
| Cashflow From Financing | 2776.6% | 1,841 | 64.00 | 1,379 | 1,802 | 2,959 | 1,011 | 6,057 | 2,460 | -6,720 | 204,610 | 524,935 | 8,265 | 4,115 | 222,600 | 617 | -3,158 | 137 | 162,004 | 483 | 4,547 | 102,785 |
NEO Income Statement
2023-09-30CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Thousands | 3 Months Ended | 9 Months Ended | ||
|---|---|---|---|---|
Sep. 30, 2023 | Sep. 30, 2022 | Sep. 30, 2023 | Sep. 30, 2022 | |
| Total net revenue | $ 151,954,000 | $ 128,782,000 | $ 436,091,000 | $ 371,023,000 |
| COST OF REVENUE | 89,643,000 | 79,889,000 | 259,075,000 | 239,952,000 |
| GROSS PROFIT | 62,311,000 | 48,893,000 | 177,016,000 | 131,071,000 |
| Operating expenses: | ||||
| General and administrative | 61,486,000 | 64,282,000 | 183,343,000 | 188,481,000 |
| Research and development | 5,285,000 | 7,312,000 | 20,182,000 | 23,651,000 |
| Sales and marketing | 17,610,000 | 16,809,000 | 52,770,000 | 50,179,000 |
| Restructuring charges | 2,125,000 | 0 | 9,883,000 | 0 |
| Total operating expenses | 86,506,000 | 88,403,000 | 266,178,000 | 262,311,000 |
| LOSS FROM OPERATIONS | (24,195,000) | (39,510,000) | (89,162,000) | (131,240,000) |
| Interest (income) expense, net | (2,840,000) | 139,000 | (6,831,000) | 2,366,000 |
| Other expense (income), net | 96,000 | (25,000) | (520,000) | 212,000 |
| Loss before taxes | (21,451,000) | (39,624,000) | (81,811,000) | (133,818,000) |
| Income tax benefit | (2,935,000) | (2,772,000) | (8,169,000) | (12,255,000) |
| NET LOSS | $ (18,516,000) | $ (36,852,000) | $ (73,642,000) | $ (121,563,000) |
| NET LOSS PER SHARE | ||||
| Basic (in dollars per share) | $ (0.15) | $ (0.30) | $ (0.59) | $ (0.98) |
| Diluted (in dollars per share) | $ (0.15) | $ (0.30) | $ (0.59) | $ (0.98) |
| WEIGHTED AVERAGE COMMON SHARES OUTSTANDING | ||||
| Basic (in shares) | 125,687 | 124,425 | 125,358 | 124,055 |
| Diluted (in shares) | 125,687 | 124,425 | 125,358 | 124,055 |
| Clinical Services | ||||
| Total net revenue | $ 127,553,000 | $ 106,162,000 | $ 365,578,000 | $ 310,588,000 |
| COST OF REVENUE | 73,994,000 | 65,261,000 | 213,032,000 | 197,563,000 |
| GROSS PROFIT | 53,559,000 | 40,901,000 | 152,546,000 | 113,025,000 |
| Advanced Diagnostics | ||||
| Total net revenue | 24,401,000 | 22,620,000 | 70,513,000 | 60,435,000 |
| COST OF REVENUE | 15,649,000 | 14,628,000 | 46,043,000 | 42,389,000 |
| GROSS PROFIT | $ 8,752,000 | $ 7,992,000 | $ 24,470,000 | $ 18,046,000 |
NEO Balance Sheet
2023-09-30CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands | Sep. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current assets | ||
| Cash and cash equivalents | $ 306,239 | $ 263,180 |
| Marketable securities, at fair value | 96,025 | 174,809 |
| Accounts receivable, net | 132,640 | 119,711 |
| Inventories | 24,053 | 24,277 |
| Prepaid assets | 18,676 | 15,237 |
| Other current assets | 9,317 | 8,077 |
| Total current assets | 586,950 | 605,291 |
| Property and equipment (net of accumulated depreciation of $154,840 and $131,930, respectively) | 94,517 | 102,499 |
| Operating lease right-of-use assets | 87,131 | 96,109 |
| Intangible assets, net | 381,910 | 408,260 |
| Goodwill | 522,766 | 522,766 |
| Other assets | 4,967 | 5,109 |
| Total non-current assets | 1,091,291 | 1,134,743 |
| Total assets | 1,678,241 | 1,740,034 |
| Current liabilities | ||
| Accounts payable | 16,819 | 20,510 |
| Accrued compensation | 47,594 | 40,141 |
| Accrued expenses and other liabilities | 18,679 | 15,070 |
| Current portion of equipment financing obligations | 4 | 70 |
| Current portion of operating lease liabilities | 6,213 | 6,584 |
| Contract liabilities | 3,617 | 7,557 |
| Total current liabilities | 92,926 | 89,932 |
| Long-term liabilities | ||
| Convertible senior notes, net | 537,475 | 535,322 |
| Operating lease liabilities | 62,007 | 68,952 |
| Deferred income tax liabilities, net | 25,370 | 34,750 |
| Other long-term liabilities | 13,035 | 13,055 |
| Total long-term liabilities | 637,887 | 652,079 |
| Total liabilities | 730,813 | 742,011 |
| Commitments and contingencies (Note 11) | ||
| Stockholders’ equity | ||
| Common stock, $0.001 par value, (250,000,000 shares authorized; 127,261,476 and 126,913,992 shares issued and outstanding, respectively) | 127 | 127 |
| Additional paid-in capital | 1,181,876 | 1,160,882 |
| Accumulated other comprehensive loss | (1,846) | (3,899) |
| Accumulated deficit | (232,729) | (159,087) |
| Total stockholders’ equity | 947,428 | 998,023 |
| Total liabilities and stockholders’ equity | $ 1,678,241 | $ 1,740,034 |
| Â CEO | Mr. Christopher Michael Smith BSc |
|---|---|
| Â WEBSITE | www.neogenomics.com |
| Â EMPLOYEES | 2100 |